Validation of Biomarkers for Prostate Cancer Prognosis
Technical Report,30 Sep 2011,29 Mar 2017
The University of Texas MD Anderson Cancer Center Houston United States
Pagination or Media Count:
Our objective is to create a multi-institutional tissue microarray resource from radical prostatectomy samples with detailed clinical information and follow-up and rigorous case-cohort design for use as a platform for validating tissue biomarkers of prognosis. In addition, we have proposed testing a series of biomarkers of prognosis and a set of biomarkers that correlate with Gleason Score. We have made significant progress over the past year. We have completed the tissue microarrays and finalized standard procedures for tissue microarray storage, sectioning and shipping. We have set up astructure for reviewing and approving biomarker proposals based on sound scientific principles and strong preliminary data. We have devised and tested a centralized distribution mechanism at Stanford University of collating and shipping TMAs to participating sites, We have found shortcomings with the BLISS system and STMAD for histological image capture and storage for pathological review and have developed a much improved, highly efficient system using a Leica scanner and Path.XL image analysis software suite. We also have made significant progress in testing TACOMA, an automater TMA scoring algorithm. We have completed staining of the TMAs for H and E, High Molecular Weight Keratin, p27, ERG, SPKINKl, Ki67 MIBl, MUCI, Survivin and PTEN FISH. Over the next year, we will expand our database to add more tested TMAS Biomarkers, perform QAQC to ensure high quality, and evaluate their performance for predicting recurrence. We will further refine TACOMA algorithm to facilitate the scoring of TMA stains. We will work with investigators to write papers reporting tested TMA Biomarkers.
- Medicine and Medical Research